NAPSA and sarcomatoid carcinoma: Approximately one-half (47.4%) of the recently described entity clear cell papillary RCC also labeled for Napsin A. Immunoreactivity for napsin A was not seen in mucinous tubular and spindle cell carcinoma or TFE/MITF RCC.